[ad_1]
The trial of the ‘Covidshield’ coxavirus vaccine has been postponed in India. AstraZeneca is developing this antidote in collaboration with the University of Oxford. The British pharmaceutical company will remain closed in India until a revaccination trial is launched, the Serum Institute of India, India’s partner in vaccines at Oxford, said on Thursday.
“We are monitoring the situation and trials of the corona vaccine in India are currently on hold,” said a brief statement from the Serum Institute.
A volunteer has fallen ill after being infected with the Oxford coronavirus vaccine. For this reason, the trial of this vaccine has been stopped for the moment by the English pharmaceutical AstraZeneca. But even after this incident, testing of that vaccine was taking place in India. The Seram Institute was conducting this trial at 16 locations across the country. That is why the Central Regulator of Drugs of the country sends its notice. India’s drug controller Gen VJ Somani asked Serem why the second and third trials were not closed until patient safety was ensured.
In response, Adar Punawala, executive director of the Seram Institute, stated that the vaccine is completely safe. So far there have been no problems in the experimental application of the vaccine in India. However, Adar Punawala said they would abide by the order to close the trial. In the end, they decided to close the trial of the vaccine for the time being to avoid a new controversy.
Earlier, an AstraZeneca spokesperson said: “An independent committee has decided to close the trial for the time being due to safety concerns during the global Oxford coronavirus tick trial.” The trial has been suspended for the time being due to unexplained illness during the trial. In the case of large trials, this disease can often occur, but it needs to be investigated, he said. However, it is unknown at this time what he will do after leaving office. Source: this time
[ad_2]
